Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: PGxRecEx01 - JSON Representation

Raw json | Download

{
  "resourceType" : "Task",
  "id" : "PGxRecEx01",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Task PGxRecEx01</b></p><a name=\"PGxRecEx01\"> </a><a name=\"hcPGxRecEx01\"> </a><a name=\"PGxRecEx01-en-US\"> </a><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title=\"Codes:{http://loinc.org LA26421-0}\">Consider alternative medication</span></p><p><b>description</b>: For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Adam B. Everyman  Male, DoB: 1951-01-20 ( Medical Record Number: m123\u00a0(use:\u00a0usual,\u00a0))</a></p><p><b>reasonReference</b>: <a href=\"Observation-TxImp01.html\">Poor metabolizer</a></p></div>"
  },
  "status" : "requested",
  "intent" : "proposal",
  "code" : {
    "coding" : [
      {
        "system" : "http://loinc.org",
        "code" : "LA26421-0",
        "display" : "Consider alternative medication"
      }
    ]
  },
  "description" : "For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/",
  "for" : {
    🔗 "reference" : "Patient/CGPatientExample01"
  },
  "reasonReference" : {
    🔗 "reference" : "Observation/TxImp01",
    "display" : "Poor metabolizer"
  }
}